Skip to menu Skip to content Skip to footer
Professor Maher Gandhi
Professor

Maher Gandhi

Email: 

Overview

Background

Maher Gandhi received his medical degree in the UK in 1989, and then trained as a haematologist, including a Fellowship in malignant haematology at Princess Margaret Cancer Centre, Toronto. He was awarded a PhD in immunology at Cambridge University under Patrick Sissons. He moved to Brisbane and from 2003-2024 worked as a Senior Staff Specialist (Pre-Eminent Status) in the Haematology / Oncology Department of the Princess Alexandra Hospital. He leads his own laboratory group and has established an international reputation studying the tumour immune microenvironment in lymphoma and its manipulation, with continuous NHMRC/MRFF funding since 2005. He was Chair of Laboratory Sciences for the Australasian Leukaemia and Lymphoma Group between 2010-2016, won the prestigious Australian Society of Medical Research Clinical Research Award in 2010 and in 2012 took up the inaugural John McCaffrey Cancer Council of Queensland / Office of Health and Medical Research Clinical Research Fellowship. Between 2011-2014 he was privileged to serve as Chair of the Metro South Human Research Ethics Committee. In 2013 he was appointed Professor of Experimental Haematology, University of Queensland, based at the Translational Research Institute, in 2014 became the inaugural Leukaemia Foundation Chair of Blood Cancer Research at the University of Queensland Frazer Institute, and was appointed Cancer Program Head in 2016. In 2018 he became Executive Director and Director of Clinical Research at Mater Research. He also continues to head the Blood Cancer Research Group, which is based in Mater Research. In 2025 to current, he was appointed Chief Executive Officer of the Translational Research Institute and its manufacturing branch TM@TRI, to serve Queenslanders by transforming health through collaborative research.

Availability

Professor Maher Gandhi is:
Available for supervision
Media expert

Qualifications

  • Bachelor of Medicine Surgery, University of Aberdeen
  • Doctor of Philosophy, University of Cambridge

Research interests

  • Lymphoma

  • Immunotherapy

  • Biomarkers

Research impacts

The research of the Blood Cancer Research Laboratory aims to understand the basis of lymphoma; to devise new treatments which are less toxic and more effective; to establish new biomarkers which will help determine the most effective treatment strategies and to monitor response and relapse and understand the development of lymphomas. The group has a strong emphasis on patient material, which it obtains from international and national clinical collaborators. Lymphomas studied includeEBV-associated lymphomas, Hodgkin Lymphoma, PTLD, Diffuse Large B-cell Lymphoma, Follicular Lymphoma and amyloidosis. We utilise a broad range of approaches including genomics, transcriptomics and functional immunoassays, and are conducting a number of MRFF funded cellular therapy studies sponsored by the Australasian Leukaemia and Lymphoma Group.

The Mater Foundation, the Leukaemia Foundation, the Mark Coghlan EBV Lymphoma Project and the Brisbane Girls Grammar School Kirsten Jack Memorial Fund are thanked for their kind support.

Works

Search Professor Maher Gandhi’s works on UQ eSpace

224 works between 1993 and 2024

201 - 220 of 224 works

2001

Conference Publication

Changes in the clonal composition of CMV-specific CD8+ cytotoxic T-lymphocytes (CTL) between allogeneic stem cell transplant recipients and their donors.

Gandhi, MK, Willis, MR, Craig, JIO, Marcus, RE, Sissons, JP and Carmichael, AJ (2001). Changes in the clonal composition of CMV-specific CD8+ cytotoxic T-lymphocytes (CTL) between allogeneic stem cell transplant recipients and their donors.. WASHINGTON: AMER SOC HEMATOLOGY.

Changes in the clonal composition of CMV-specific CD8+ cytotoxic T-lymphocytes (CTL) between allogeneic stem cell transplant recipients and their donors.

2001

Journal Article

Antibody responses to vaccinations given within the first two years after transplant are similar between autologous peripheral blood stem cell and bone marrow transplant recipients

Gandhi, MK, Egner, W, Sizer, L, Inman, I, Zambon, M, Craig, JIO and Marcus, RE (2001). Antibody responses to vaccinations given within the first two years after transplant are similar between autologous peripheral blood stem cell and bone marrow transplant recipients. Bone Marrow Transplantation, 28 (8), 775-781. doi: 10.1038/sj.bmt.1703239

Antibody responses to vaccinations given within the first two years after transplant are similar between autologous peripheral blood stem cell and bone marrow transplant recipients

2000

Conference Publication

The clonal reconstitution of human cytomegalovirus-specific memory cytotoxic T-lymphocytes following allogeneic stem cell transplantation.

Gandhi, MK, Carmichael, AJ, Wills, MR, Craig, JIO, Marcus, RE and Sissons, JP (2000). The clonal reconstitution of human cytomegalovirus-specific memory cytotoxic T-lymphocytes following allogeneic stem cell transplantation.. WASHINGTON: AMER SOC HEMATOLOGY.

The clonal reconstitution of human cytomegalovirus-specific memory cytotoxic T-lymphocytes following allogeneic stem cell transplantation.

2000

Journal Article

A comparison of molecular and enzyme-based assays for the detection of thiopurine methyltransferase mutations

Coulthard, SA, Rabello, C, Robson, J, Howell, C, Minto, L, Middleton, PG, Gandhi, MK, Jackson, G, McLelland, J, O'Brien, H, Smith, S, Reid, MM, Pearson, ADJ and Hall, AG (2000). A comparison of molecular and enzyme-based assays for the detection of thiopurine methyltransferase mutations. British Journal of Haematology, 110 (3), 599-604. doi: 10.1046/j.1365-2141.2000.02218.x

A comparison of molecular and enzyme-based assays for the detection of thiopurine methyltransferase mutations

2000

Journal Article

Status of Cytomegalovirus prevention and treatment in 2000

Zaia, John A., Sissons, J. G. Patrick, Riddell, Stanley, Diamond, Don J., Wills, M. R., Carmichael, A. J., Weekes, M. P., Gandhi, M., La Rosa, C., Villacres, M., Lacey, S., Markel, S. and Sun, J. (2000). Status of Cytomegalovirus prevention and treatment in 2000. Hematology, 339-355. doi: 10.1182/asheducation-2000.1.339

Status of Cytomegalovirus prevention and treatment in 2000

1999

Journal Article

A comparison of CD34(+) cell selected and unselected autologous peripheral blood stem cell transplantation for multiple myeloma: a case controlled analysis

Gandhi, MK, Jestice, HK, Scott, MA, Bloxham, DM, Bass, G, Craig, JIO and Marcus, RE (1999). A comparison of CD34(+) cell selected and unselected autologous peripheral blood stem cell transplantation for multiple myeloma: a case controlled analysis. Bone Marrow Transplantation, 24 (4), 369-375. doi: 10.1038/sj.bmt.1701938

A comparison of CD34(+) cell selected and unselected autologous peripheral blood stem cell transplantation for multiple myeloma: a case controlled analysis

1999

Conference Publication

Influenza vaccination is ineffective in the first 2 years after stem cell transplant.

Gandhi, MK, Egner, W, Inman, I, Craig, JIO and Marcus, RE (1999). Influenza vaccination is ineffective in the first 2 years after stem cell transplant.. OXFORD: BLACKWELL SCIENCE LTD.

Influenza vaccination is ineffective in the first 2 years after stem cell transplant.

1999

Conference Publication

A case controlled comparison between CD34(+) cell selected and unselected autologous PBSCT for multiple myeloma.

Gandhi, MK, Jestice, HK, Scott, MA, Bloxham, DM, Bass, G, Craig, J and Marcus, RE (1999). A case controlled comparison between CD34(+) cell selected and unselected autologous PBSCT for multiple myeloma.. BASINGSTOKE: STOCKTON PRESS.

A case controlled comparison between CD34(+) cell selected and unselected autologous PBSCT for multiple myeloma.

1999

Journal Article

The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients

Gandhi, MK, Jestice, K, Scott, MA, Bloxham, D, Bass, G and Marcus, RE (1999). The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients. Bone Marrow Transplantation, 23 (1), 9-13. doi: 10.1038/sj.bmt.1701530

The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients

1998

Journal Article

A trend towards an increased incidence of chronic graft-versus-host disease following allogeneic peripheral blood progenitor cell transplantation: a case controlled study

Scott, MA, Gandhi, MK, Jestice, HK, Mahendra, P, Bass, G and Marcus, RE (1998). A trend towards an increased incidence of chronic graft-versus-host disease following allogeneic peripheral blood progenitor cell transplantation: a case controlled study. Bone Marrow Transplantation, 22 (3), 273-276. doi: 10.1038/sj.bmt.1701327

A trend towards an increased incidence of chronic graft-versus-host disease following allogeneic peripheral blood progenitor cell transplantation: a case controlled study

1998

Conference Publication

Reduced bone mineral density (BMD) in males and females after bone marrow transplant (BMT).

Gandhi, MK, Sizer, L, Compston, JE, Prevost, A and Marcus, RE (1998). Reduced bone mineral density (BMD) in males and females after bone marrow transplant (BMT).. OXFORD: AMER SOC HEMATOLOGY.

Reduced bone mineral density (BMD) in males and females after bone marrow transplant (BMT).

1998

Conference Publication

Allogeneic peripheral blood progenitor cell transplantation: A case controlled study of GVHD.

Scott, MA, Gandhi, MK, Jestice, HK, Mahendra, P and Marcus, RE (1998). Allogeneic peripheral blood progenitor cell transplantation: A case controlled study of GVHD.. BASINGSTOKE: STOCKTON PRESS.

Allogeneic peripheral blood progenitor cell transplantation: A case controlled study of GVHD.

1997

Conference Publication

Febrile neutropenia after hematopoietic stem cell mobilization with chemotherapy and G-CSF does not affect collection of adequate numbers of CD34+ cells.

Yee, K, Tu, JV, MacKinnon, J, Gandhi, M, Stewart, AK, Saragosa, R, Keating, A and Crump, M (1997). Febrile neutropenia after hematopoietic stem cell mobilization with chemotherapy and G-CSF does not affect collection of adequate numbers of CD34+ cells.. PHILADELPHIA: W B SAUNDERS CO.

Febrile neutropenia after hematopoietic stem cell mobilization with chemotherapy and G-CSF does not affect collection of adequate numbers of CD34+ cells.

1997

Conference Publication

Qualitative difference in CD34 counts in multiple myeloma (MM) and breast cancer (BCa) patient (PT) stem cell grafts.

Simpson, DR, Gandhi, MK, Stewart, AK, Crump, M and Keating, A (1997). Qualitative difference in CD34 counts in multiple myeloma (MM) and breast cancer (BCa) patient (PT) stem cell grafts.. CHARLOTTESVILLE: CARDEN JENNINGS PUBL CO LTD.

Qualitative difference in CD34 counts in multiple myeloma (MM) and breast cancer (BCa) patient (PT) stem cell grafts.

1997

Conference Publication

Autologous marrow and/or blood cell transplantation (ABMT) for follicular large cell lymphoma (FLC)

Simpson, DR, Gandhi, MK, Stewart, AK, Crump, M and Keating, A (1997). Autologous marrow and/or blood cell transplantation (ABMT) for follicular large cell lymphoma (FLC). CHARLOTTESVILLE: CARDEN JENNINGS PUBL CO LTD.

Autologous marrow and/or blood cell transplantation (ABMT) for follicular large cell lymphoma (FLC)

1997

Conference Publication

Febrile neutropenia does not affect collection of adequate CD34+ cells after mobilization with chemotherapy and G-CSF

Yee, K, Tu, JV, MacKinnon, J, Gandhi, M, Stewart, AK, Saragosa, R, Keating, A and Crump, M (1997). Febrile neutropenia does not affect collection of adequate CD34+ cells after mobilization with chemotherapy and G-CSF. CHARLOTTESVILLE: CARDEN JENNINGS PUBL CO LTD.

Febrile neutropenia does not affect collection of adequate CD34+ cells after mobilization with chemotherapy and G-CSF

1997

Conference Publication

Pre-autologous bone marrow transplant (ABMT) screening for HLA antibodies does not predict for platelet alloimmunization post-ABMT: A case controlled study

Gandhi, MK, Simpson, D, Yee, K, MacKinnon, J, Stewart, AK, Crump, M and Keating, A (1997). Pre-autologous bone marrow transplant (ABMT) screening for HLA antibodies does not predict for platelet alloimmunization post-ABMT: A case controlled study. CHARLOTTESVILLE: CARDEN JENNINGS PUBL CO LTD.

Pre-autologous bone marrow transplant (ABMT) screening for HLA antibodies does not predict for platelet alloimmunization post-ABMT: A case controlled study

1996

Conference Publication

A multicentre study of granulocyte-macrophage colony stimulating factor (GM-CSF) in combination with consolidation therapy in adult acute myeloid leukemia (AML).

Keating, A, Gandhi, MK, Crump, M, Smith, A, Belch, A and Baker, MA (1996). A multicentre study of granulocyte-macrophage colony stimulating factor (GM-CSF) in combination with consolidation therapy in adult acute myeloid leukemia (AML).. PHILADELPHIA: W B SAUNDERS CO.

A multicentre study of granulocyte-macrophage colony stimulating factor (GM-CSF) in combination with consolidation therapy in adult acute myeloid leukemia (AML).

1996

Conference Publication

Treatment of acute myeloid leukemia (AML) at diagnosis in 99 unselected adults with high dose ARA-C (HIDAC) and mitoxantrone: Long-term follow-up.

Keating, A, Gandhi, MK, Crump, M, Smith, A, Belch, A and Baker, MA (1996). Treatment of acute myeloid leukemia (AML) at diagnosis in 99 unselected adults with high dose ARA-C (HIDAC) and mitoxantrone: Long-term follow-up.. PHILADELPHIA: W B SAUNDERS CO.

Treatment of acute myeloid leukemia (AML) at diagnosis in 99 unselected adults with high dose ARA-C (HIDAC) and mitoxantrone: Long-term follow-up.

1996

Conference Publication

Congenital deficiency of thiopurine methyltransferase as a cause of pancytopenia in patients treated with azathioprine

Hall, AG, Rabello, C, Jackson, G, Gandhi, MK and OBrien, H (1996). Congenital deficiency of thiopurine methyltransferase as a cause of pancytopenia in patients treated with azathioprine. OXFORD: BLACKWELL SCIENCE LTD.

Congenital deficiency of thiopurine methyltransferase as a cause of pancytopenia in patients treated with azathioprine

Funding

Current funding

  • 2025 - 2027
    Personalized immunotherapy for the treatment of light chain amyloidosis
    Snowdome Haematology Fellowship
    Open grant
  • 2024 - 2029
    BrainCAR19 Study- Treatment of relapsed Primary Brain Lymphoma with CD19 directed CAR-T cells
    NHMRC MRFF CTA - Clinical Trials Activity
    Open grant
  • 2023 - 2025
    Metabolic Reprogramming of Malignant B-cells Impairs Immune-Fitness of Intratumoral T-Cells in Follicular Lymphoma
    Conquer Cancer AstraZeneca Young Investigator Award
    Open grant
  • 2019 - 2026
    An Open Label, Multicentre, Phase One Study Incorporating Early Application of CAR T cells for Primary Refractory Aggressive Lymphoma
    NHMRC MRFF - Rare Cancers, Rare Diseases and Unmet Need
    Open grant
  • 2018 - 2025
    An Open label, Multicentre, Phase I study of Ibrutinib, Rituximab and EBV specific T-cells in Patients with EBV-positive Primary or Secondary CNS Lymphoma unsuitable for standard therapies
    NHMRC MRFF - Lifting Clinical Trials Registries Capacity
    Open grant

Past funding

  • 2020 - 2022
    PiggyBac transposon UCB-CAR19-NK cells: a novel off-the-shelf cellular immunotherapy for children with CD19+ blood cancers
    Children's Hospital Foundation Immunotherapy Research Grants
    Open grant
  • 2019 - 2020
    Indolent Lymphoma: Establishing a prognostic score fit for the modern era
    The Leukaemia Foundation of Australia Limited
    Open grant
  • 2018 - 2019
    A novel immunotherapy strategy for lymphoma using artificial microRNA gene targeting
    Metro South Hospital and Health Service
    Open grant
  • 2018 - 2022
    Integrating immunity and genetics in Follicular Lymphoma to establish a prognostic score fit for the modern era
    NHMRC Project Grant
    Open grant
  • 2017 - 2019
    Pre-clinical studies of anti-LAG3 in lymphoma
    Bristol-Myers Squibb Pharmaceuticals Pty Limited
    Open grant
  • 2017
    Improving the evidence base for resource allocation in indolent lymphoma
    Gilead Australia Fellowship
    Open grant
  • 2016 - 2018
    Prognosticator for Follicular lymphoma (FL) and Mantle celly lymphoma (MCL)
    Research Donation Generic
    Open grant
  • 2016 - 2017
    Blood biomarkers in Hodgkin Lymphoma
    PA Research Foundation NHMRC Infrastructure Support
    Open grant
  • 2016
    Marshaling NK-cells in the fight against blood cancers: a novel approach
    PA Research Foundation NHMRC Near Miss Grant
    Open grant
  • 2015 - 2016
    Funding Assistance for Gandhi laboratory
    Metro South Hospital and Health Service
    Open grant
  • 2015 - 2016
    Using single-cell transcriptomics to define T-cell tolerance in EBV+ lymphoma
    PA Research Foundation
    Open grant
  • 2014 - 2018
    Leukaemia Foundation Queensland Chair in Blood Cancer Research (2014-2019)
    Leukaemia Foundation
    Open grant
  • 2014 - 2017
    Circulating Biomarkers in advanced classical Hodgkin Lymphoma
    NHMRC Project Grant
    Open grant
  • 2013 - 2020
    The Diamantina Individualised Oncology Care Centre (DIOCC)
    Australian Cancer Research Foundation
    Open grant
  • 2013 - 2014
    Monocytic myeloid derived suppressor cells and antiCD20-antibody dependent cellular cytotoxicity in diffuse large B-cell lymphoma (Cancer Council Queensland grant administered by PAH)
    Metro South Hospital and Health Service
    Open grant

Supervision

Availability

Professor Maher Gandhi is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Supervision history

Current supervision

Completed supervision

Media

Enquiries

Contact Professor Maher Gandhi directly for media enquiries about:

  • Biomarkers
  • Immunotherapy
  • Lymphoma

Need help?

For help with finding experts, story ideas and media enquiries, contact our Media team:

communications@uq.edu.au